Not v uncommon in obese children/adults, which is logical. But non-alcoholic fatty liver disease (NAFLD) may progress to steatofibrosis, non-alcoholic steatohepatitis (NASH), cirrhosis, liver failure and hepatocellular carcinoma. It is now amongst the top three indications for liver transplantation in adults.
And not all cases are obese.
Alcoholic fatty liver disease is a different thing – depends on type of beverage, genetic risk factors, drinking pattern, duration of exposure etc so unpredictable.
Particularly likely to progress when co-exists with metabolic syndrome (obesity esp high waist circumference, high blood pressure, high insulin resistance, high lipids). Some polymorphisms also contribute higher risk of progressive disease. So family history important too.
Some drugs can contribute, including methotrexate, steroids, valproate.
On examination, look for acanthosis nigricans (marker of insulin resistance) as well as signs of chronic liver disease. Hepatomegaly suggests an alternative diagnosis.
Essentially to assess co-morbidity and exclude other causes:
- Fasting serum glucose/ insulin.
- HOMA-IR (fasting glucose x fasting insulin/ 22.5)
- HbA1c measurement
- Renal function tests
- Vitamin D level
- Assessment of liver function and screening for other causes of raised transaminases/ steatosis
- First Line Investigations: ALT, AST, ALP, GGT, Split bilirubin, FBC, Coagulation screen, Albumin, Fasting lipid profile, Immunogloblins and complement levels, Autoimmune profile including ANCA, Anti-transglutaminase antibodies, Thyroid function tests, A1AT level and phenotype, Copper and caeruloplasmin, Plasma free fatty acids, amino acids, organic acids, uric acid, acylcarnitines, and lactate, Hepatitis A, B, C and E serology
- Second line investigations: If raised triglyceride level consider Lysosomal acid lipase, 24-hour urine copper collection, ophthalmic examination and/ or genetic testing for Wilson’s disease. If organomegaly/ raised uric acid/ raised lactate or a history of hypoglycaemia consider genetic testing for glycogen storage disease
Non-invasive measures of fibrosis available in some centres.
Reasons to refer to liver unit
- Age < 10yr
- Evidence of alternative cause for steatosis detected through screening investigations
- Presence of metabolic syndrome, type 2 diabetes mellitus, and/ or hyperlipidaemia
- Increased AST/ALT ratio (>1) and/or a raised AST/ ALT (≥80IU/L)
- Raised serum level of GGT
- Child has panhypopituitarism
- Raised non-invasive marker of fibrosis measurement
- Presence of hepatomegaly/splenomegaly
- Synthetic dysfunction (raised PT or low albumin level)
[Caroline says only if double normal)
Patient information leaflets and guidance for NAFLD are available via the Children’s Liver Disease Foundation at https://www.childliverdisease.org
[BSPGHAN 2020 guideline]